Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesMid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation
Cardiology in the Young, 10/19/09
Giordano U et al. – Atenolol was prescribed for those with elevated values of blood pressure but with a normal increment of heart rate during exercise. The authors prescribed Candesartan for those with elevated levels of blood pressure but with reduced increments of heart rate, specifically maximal heart rates of less than 85% of their predicted value. Both drugs were used when one alone was not effective. They found that, in young patients, candesartan provided better control of blood pressure with no side–effects, especially as demonstrated using 24–hour ambulatory monitoring, while atenolol was less effective, with more side–effects. Their experience suggests that both drugs should be used in patients who are non–responsive to monotherapy.
Ugo Giordano, 10/21/09
| It's necessary for patients after coarctation repair to have a close follow-up for the control of their blood pressure to avoid end-organ damage. Candesartan (as an Angiotensin receptor blocker) should be the first choice for the treatment of hypertension in these patients. The association with a beta-blocker (in our experience Atenolol) should be considered if the hypertensive response persists after treatment with Candesartan. |
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
Journal of Human Hypertension, 11/10/09
Sponsor
Article Search
Sponsor